Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Ludwig Institute for Cancer Research Ltd. has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters span 5 distinct examiners and 5 distinct art units. TRAN, ERIC is the busiest examiner, with 1 pending matter.
The pending work is fully distributed across the identified examination channels. This dispersion suggests that application-specific analysis will be important, especially where biological subject matter, therapeutic use, or molecular limitations are treated differently by different examiners.
No examiner is shown as handling more than the stated 1 pending matter. Counsel can still coordinate the portfolio through consistent technical definitions, shared disclosure mapping, and an evidence plan, while keeping each amendment and prior-art response tied to the particular application.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RILEY, JEZIA | 1 | 83.0% | +7.2% |
| KIM, SEONG JONG | 1 | 25.0% | +0.0% |
| PHAM, KHAI QUYNH TIEN | 1 | 0.0% | +0.0% |
| BAUSCH, SARAE L | 1 | 29.7% | +45.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18781157 | BISULFITE-FREE, BASE-RESOLUTION IDENTIFICATION OF CYTOSINE MODIFICATIONS | RILEY, JEZIA | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17746748 | METHODS AND COMPOSITIONS FOR DETECTING ecDNA | BAUSCH, SARAE L | 243d overdue |
| 18579221 | Use Of Methanol And Prodrugs Thereof In Therapy | KIM, SEONG JONG | — |
| 18001898 | PARALLEL ANALYSIS OF INDIVIDUAL CELLS FOR RNA EXPRESSION AND DNA FROM TARGETED TAGMENTATION BY SEQUENCING | PHAM, KHAI QUYNH TIEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17746748 | METHODS AND COMPOSITIONS FOR DETECTING ecDNA | BAUSCH, SARAE L | 243d overdue |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| 1621 | 1 |
| 1684 | 1 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18781157 | BISULFITE-FREE, BASE-RESOLUTION IDENTIFICATION OF CYTOSINE MODIFICATIONS | RILEY, JEZIA | 1681 | §103Other | Non-Final OA | — | Pending | Jul 23, 2024 |
| 18579221 | Use Of Methanol And Prodrugs Thereof In Therapy | KIM, SEONG JONG | 1621 | §103§112 | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18001898 | PARALLEL ANALYSIS OF INDIVIDUAL CELLS FOR RNA EXPRESSION AND DNA FROM TARGETED TAGMENTATION BY SEQUENCING | PHAM, KHAI QUYNH TIEN | 1684 | §103 | Non-Final OA | — | Pending | Dec 15, 2022 |
| 17746748 | METHODS AND COMPOSITIONS FOR DETECTING ecDNA | BAUSCH, SARAE L | 1699 | §103§112 | Final Rejection | 243d overdue | Pending | May 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLudwig Institute for Cancer Research Ltd. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Jezia Riley has the most, with 1 of Ludwig Institute for Cancer Research Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
